Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Maggie, Cheang"'
Autor:
Aruna Korlimarla, PS Hari, Jyoti Prabhu, Chanthirika Ragulan, Yatish Patil, VP Snijesh, Krisha Desai, Aju Mathews, Sandhya Appachu, Ravi B. Diwakar, BS Srinath, Alan Melcher, Maggie Cheang, Anguraj Sadanandam
Publikováno v:
Translational Oncology, Vol 27, Iss , Pp 101574- (2023)
Externí odkaz:
https://doaj.org/article/8af7d49800d6483188b46b69120e86c7
Autor:
Aruna Korlimarla, Hari PS, Jyoti Prabhu, Chanthirika Ragulan, Yatish Patil, Snijesh VP, Krisha Desai, Aju Mathews, Sandhya Appachu, Ravi B. Diwakar, Srinath BS, Alan Melcher, Maggie Cheang, Anguraj Sadanandam
Publikováno v:
Translational Oncology, Vol 25, Iss , Pp 101511- (2022)
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease with a significant challenge to effectively manage in the clinic worldwide. Immunotherapy may be beneficial to TNBC patients if responders can be effectively identified. Here we
Externí odkaz:
https://doaj.org/article/a88adf8242244906823d8dcfed4bdb5f
Autor:
Max Robinson, Jacqueline James, Gareth Thomas, Nicholas West, Louise Jones, Jessica Lee, Karin Oien, Alex Freeman, Clare Craig, Philip Sloan, Philip Elliot, Maggie Cheang, Manuel Rodriguez‐Justo, Clare Verrill, on behalf of the UK National Cancer Research Institute (NCRI) Cellular‐Molecular Pathology (CM‐Path) clinical trials working group
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 5, Iss 2, Pp 91-99 (2019)
Abstract While pathologists have always played a pivotal role in clinical trials ensuring accurate diagnosis and staging, pathology data from prognostic and predictive tests are increasingly being used to enrol, stratify and randomise patients to exp
Externí odkaz:
https://doaj.org/article/d459fef61ef049c2b199746608d46e1a
Autor:
Patrycja Gazinska, Charlotte Milton, Jacopo Iacovacci, Joseph Ward, Richard Buus, Thanussuyah Alaguthurai, Rosalind Graham, Ayse Akarca, Esther Lips, Kalnisha Naidoo, Jelle Wesseling, Teresa Marafioti, Maggie Cheang, Cheryl Gillett, Yin Wu, Aadil Khan, Alan Melcher, Roberto Salgado, Mitch Dowsett, Andrew Tutt, Ioannis Roxanis, Syed Haider, Sheeba Irshad
Publikováno v:
Clinical Cancer Research. 28:4494-4508
Purpose: To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)–resistant triple-negative breast cancer (TNBC) and ER+HER2– breast cancer disease. Experimental Design: Following pathology review, 153 patients were identified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c2e2e7b9ceb92aae7e00f0f1d6342e7
https://doi.org/10.1158/1078-0432.ccr-22-0543
https://doi.org/10.1158/1078-0432.ccr-22-0543
Autor:
Sheeba Irshad, Syed Haider, Ioannis Roxanis, Andrew Tutt, Mitch Dowsett, Roberto Salgado, Alan Melcher, Aadil Khan, Yin Wu, Cheryl Gillett, Maggie Cheang, Teresa Marafioti, Jelle Wesseling, Kalnisha Naidoo, Esther Lips, Ayse Akarca, Rosalind Graham, Thanussuyah Alaguthurai, Richard Buus, Joseph Ward, Jacopo Iacovacci, Charlotte Milton, Patrycja Gazinska
Supplementary Data from Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11bdf077fc6d6dd8c21f3d4689e8a136
https://doi.org/10.1158/1078-0432.22488345.v1
https://doi.org/10.1158/1078-0432.22488345.v1
Autor:
Sheeba Irshad, Syed Haider, Ioannis Roxanis, Andrew Tutt, Mitch Dowsett, Roberto Salgado, Alan Melcher, Aadil Khan, Yin Wu, Cheryl Gillett, Maggie Cheang, Teresa Marafioti, Jelle Wesseling, Kalnisha Naidoo, Esther Lips, Ayse Akarca, Rosalind Graham, Thanussuyah Alaguthurai, Richard Buus, Joseph Ward, Jacopo Iacovacci, Charlotte Milton, Patrycja Gazinska
Supplementary Figure from Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a90ac325e4ea4104b5c74dea910e71b
https://doi.org/10.1158/1078-0432.22488333.v1
https://doi.org/10.1158/1078-0432.22488333.v1
Autor:
Sheeba Irshad, Syed Haider, Ioannis Roxanis, Andrew Tutt, Mitch Dowsett, Roberto Salgado, Alan Melcher, Aadil Khan, Yin Wu, Cheryl Gillett, Maggie Cheang, Teresa Marafioti, Jelle Wesseling, Kalnisha Naidoo, Esther Lips, Ayse Akarca, Rosalind Graham, Thanussuyah Alaguthurai, Richard Buus, Joseph Ward, Jacopo Iacovacci, Charlotte Milton, Patrycja Gazinska
Purpose:To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)–resistant triple-negative breast cancer (TNBC) and ER+HER2– breast cancer disease.Experimental Design:Following pathology review, 153 patients were identified as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29e40a24c6ba425cfc4f07a27c59609d
https://doi.org/10.1158/1078-0432.c.6532695.v1
https://doi.org/10.1158/1078-0432.c.6532695.v1
Autor:
Maggie Cheang, Mitch Dowsett, Mothaffar Rimawi, Stephen Johnston, Samuel Jacobs, Judith Bliss, Katherine Pogue-Geile, Lucy Kilburn, Zhou Zhu, Eugene F. Schuster, Hui Xiao, Lisa Swaim, Shibing Deng, Dongrui R. Lu, Eric Gauthier, Jennifer Tursi, Dennis J. Slamon, Hope S. Rugo, Richard S. Finn, Yuan Liu
Publikováno v:
Cancer Research. 82:PD2-07
Background Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients (pts) with breast cancer (BC) treated with chemotherapy, human epidermal growth factor receptor 2 (HER2) targeted therapies, and e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b629f42dbff05fef9c0498b3fed539f
https://doi.org/10.1158/1538-7445.sabcs21-pd2-07
https://doi.org/10.1158/1538-7445.sabcs21-pd2-07
Autor:
Stephen Johnston, Judith M. Bliss, Claire Swift, Nick Turner, Chris Holcombe, Sophie Perry, Maggie Cheang, Vera Martins, Andrew Dodson, Shannon Puhalla, Melanie Finnigan, Samuel A. Jacobs, Yuan Liu, Katherine Pogue-Geile, C. Kent Osborne, Mothaffar F. Rimawi, Lucy Kilburn, Mitch Dowsett
Purpose:To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER+/HER2− breast cancer; and (ii) the pharmacodynamic effect of the agents on the bio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2279285765c81c0e79596b56399a3d4e
https://doi.org/10.1158/1078-0432.c.6531375.v1
https://doi.org/10.1158/1078-0432.c.6531375.v1
Autor:
Stephen Johnston, Judith M. Bliss, Claire Swift, Nick Turner, Chris Holcombe, Sophie Perry, Maggie Cheang, Vera Martins, Andrew Dodson, Shannon Puhalla, Melanie Finnigan, Samuel A. Jacobs, Yuan Liu, Katherine Pogue-Geile, C. Kent Osborne, Mothaffar F. Rimawi, Lucy Kilburn, Mitch Dowsett
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e361d5674cd4ee2e32f3d48facbc707
https://doi.org/10.1158/1078-0432.22484283
https://doi.org/10.1158/1078-0432.22484283